1697P Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis
| Autor: | Sadeghi, S., Parikh, R., Appleman, L.J., Tsao-Wei, D., Groshen, S., Li, M., Tagawa, S.T., Nanus, D.M., Molina, A.M., Ornstein, M.C., Rini, B.I., Dreicer, R., Quinn, D.I., Lara, P.N. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S1017-S1017 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|